September 11, 2015 Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy
September 3, 2015 Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
August 18, 2015 Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
August 14, 2015 Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015
August 6, 2015 Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
July 1, 2015 Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
June 22, 2015 Capricor Therapeutics, Inc. (Nasdaq: CAPR) to Ring The Nasdaq Stock Market Closing Bell
June 22, 2015 Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
June 17, 2015 Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies
June 15, 2015 Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET
June 8, 2015 Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
June 2, 2015 Kite Pharma Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting
